In vivo pharmacodynamic activity of the glycopeptide dalbavancin
about
Dalbavancin in the treatment of complicated skin and soft-tissue infections: a reviewClinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI)Dalbavancin for the treatment of acute bacterial skin and skin structure infectionsActivity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax modelIn vivo pharmacodynamics of new lipopeptide MX-2401Extended-duration dosing and distribution of dalbavancin into bone and articular tissue.Pharmacokinetics/pharmacodynamics of marbofloxacin in a Pasteurella multocida serious murine lung infection model.Dalbavancin: A Novel Lipoglycopeptide Antibiotic with Extended Activity Against Gram-Positive Infections.Area under the curve predictions of dalbavancin, a new lipoglycopeptide agent, using the end of intravenous infusion concentration data point by regression analyses such as linear, log-linear and power models.Pharmacokinetics, Safety, and Tolerability of a Single 500-mg or 1000-mg Intravenous Dose of Dalbavancin in Healthy Japanese Subjects.Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia modelIn vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model.A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection.Dalbavancin, a long-acting lipoglycopeptide for the treatment of multidrug-resistant Gram-positive bacteria.In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model.Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections.Current challenges in treating MRSA: what are the options?A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.Current and prospective treatments for multidrug-resistant gram-positive infections.Dalbavancin (BI-387) for the treatment of complicated skin and skin structure infection.The interaction of mannose binding lectin (MBL) with mannose containing glycopeptides and the resultant potential impact on invasive fungal infection.Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections.Glycopeptide antibiotics: evolving resistance, pharmacology and adverse event profile.Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram-Positive Infections.Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.Comparative Pharmacodynamics of Telavancin and Vancomycin in the Neutropenic Murine Thigh and Lung Infection Models against Staphylococcus aureus.Dosing strategies to optimize currently available anti-MRSA treatment options (Part 1: IV options).Translational PK/PD of anti-infective therapeutics.Single-Dose Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections.Dalbavancin Activity When Tested against Streptococcus pneumoniae Isolated in Medical Centers on Six Continents (2011 to 2014).Impact of Glycopeptide Resistance in Staphylococcus aureus on the Dalbavancin In Vivo Pharmacodynamic Target.Pharmacokinetic-pharmacodynamic modeling of dalbavancin, a novel glycopeptide antibiotic.Monte Carlo simulation analysis of ceftobiprole, dalbavancin, daptomycin, tigecycline, linezolid and vancomycin pharmacodynamics against intensive care unit-isolated methicillin-resistant Staphylococcus aureus.Update on prevalence and treatment of methicillin-resistant Staphylococcus aureus infections.Multiple Weekly Dalbavancin Dosing for the Treatment of Native Vertebral Osteomyelitis Caused by Methicillin-Resistant Staphylococcus Aureus: A Case Report.The role of dalbavancin in the multi-disciplinary management of wound infections in orthopaedic surgery.Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides.
P2860
Q24647429-EA629BA9-1B7A-4E4E-923B-548FB76717B1Q26746208-8199AFDB-B7F5-416D-8F42-E42F2D6832C1Q26799598-76F9CC3D-EEB7-4F81-9B95-D27214D995BEQ33676316-4F3034D0-C45C-4E88-8DC8-5793189C3204Q34309486-850A8593-A062-4586-90CC-B9AE413EA2C9Q35168936-5FE8BFAC-F89B-4AC0-8041-9115B5E95211Q35859460-EC808A3A-43C7-41A7-AD9A-C795C479F54CQ36073405-78A60803-631A-4D06-82B0-9DB5989F24D9Q36307070-A90D052C-F68F-4075-ABEB-987D3D40115AQ36319908-453F1006-AB88-4203-9EA5-F60C195FBD36Q36364009-C0A6A732-3C2B-485D-8B95-286EDFFD4BBAQ36425025-EB0AD03C-4C0B-4A2A-8B27-8C7C0DF08C18Q36543866-3641459A-F651-4CE9-924B-2BB5195A81B9Q36901937-0DFF1155-12FE-4A2E-AB15-B9199F41C935Q36932989-91ECE4E7-45E3-49A4-B98A-B6359F99E89CQ37077627-CA8A86D0-FF70-44E7-B088-567A7EB3A3D2Q37291338-2DCD166D-823A-4A6A-9402-D9D0D8A6F89CQ37661510-135975E0-4AF2-400C-B4EB-81FCE274FCCCQ38123255-A587D9D5-E84B-4FD7-8FF8-46DBE3315972Q38314386-2DA9D597-8CBD-444A-B9FB-35C4DA91C057Q38356990-71596677-318C-4825-BDFB-93C14A28FF4EQ38536284-0EAC4ECE-88D2-4E12-BC8A-B879A3447B55Q38545589-7F83CCCD-D27A-476E-9CCC-64D4B8400C7BQ38615330-41CC765A-A54B-4503-A312-B92AFF8AAC0BQ38646905-A022F50E-5CDD-4C7E-95C5-83C421E87E89Q38833633-2FB959E2-E863-4BF9-AC8F-B644B3C95058Q38907793-4EC9B9B9-3612-4B93-AF17-B94AC1A3E462Q39039505-889D0893-C87F-4872-8AA7-0E113751B8ACQ39042375-583803A5-7922-4B1C-B535-A65063CBDF0FQ40746046-F0571CC0-397B-4800-B52B-0DC03E3FF09BQ40988669-9D1286EB-EE53-4D27-A8F8-419CCF728E6BQ43405839-A6C04B44-E47E-490F-9689-AB54ABC6E4ABQ46255695-D16B4005-0A81-4F95-9A35-6196BB5A2B67Q46274310-D0DB4E82-438E-42C9-BFE5-9F40321C7ECCQ47140222-5BC5E301-3EB8-4572-95C7-20191209FBF0Q48247125-C6C8CF8D-2D44-4E90-BBFB-E66E9749CD6DQ50053159-417ED396-E485-4942-841E-BF855C040ACA
P2860
In vivo pharmacodynamic activity of the glycopeptide dalbavancin
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
In vivo pharmacodynamic activity of the glycopeptide dalbavancin
@ast
In vivo pharmacodynamic activity of the glycopeptide dalbavancin
@en
type
label
In vivo pharmacodynamic activity of the glycopeptide dalbavancin
@ast
In vivo pharmacodynamic activity of the glycopeptide dalbavancin
@en
prefLabel
In vivo pharmacodynamic activity of the glycopeptide dalbavancin
@ast
In vivo pharmacodynamic activity of the glycopeptide dalbavancin
@en
P2860
P356
P1476
In vivo pharmacodynamic activity of the glycopeptide dalbavancin
@en
P2093
William A Craig
P2860
P304
P356
10.1128/AAC.01264-06
P407
P50
P577
2007-02-16T00:00:00Z